Duration of exposure by randomized treatment group (double-blind phase; safety population)
| Duration of exposure . | Placebo (n = 67), n (%) . | Lenalidomide 5 mg (n = 69), n (%) . | Lenalidomide 10 mg (n = 69), n (%) . |
|---|---|---|---|
| ≥ 4 weeks | 63 (94.0) | 67 (97.1) | 63 (91.3) |
| ≥ 8 weeks | 62 (92.5) | 62 (89.9) | 59 (85.5) |
| ≥ 16 weeks* | 42 (62.7) | 50 (72.5) | 54 (78.3) |
| ≥ 24 weeks | 6 (9.0) | 30 (43.5) | 41 (59.4) |
| ≥ 32 weeks | 4 (6.0) | 29 (42.0) | 39 (56.5) |
| ≥ 52 weeks | 3 (4.5) | 15 (21.7) | 29 (42.0) |
| Duration of exposure . | Placebo (n = 67), n (%) . | Lenalidomide 5 mg (n = 69), n (%) . | Lenalidomide 10 mg (n = 69), n (%) . |
|---|---|---|---|
| ≥ 4 weeks | 63 (94.0) | 67 (97.1) | 63 (91.3) |
| ≥ 8 weeks | 62 (92.5) | 62 (89.9) | 59 (85.5) |
| ≥ 16 weeks* | 42 (62.7) | 50 (72.5) | 54 (78.3) |
| ≥ 24 weeks | 6 (9.0) | 30 (43.5) | 41 (59.4) |
| ≥ 32 weeks | 4 (6.0) | 29 (42.0) | 39 (56.5) |
| ≥ 52 weeks | 3 (4.5) | 15 (21.7) | 29 (42.0) |
The reduction in patient numbers after 16 weeks is the result of the crossover design of the study.